Retatrutide
5 mg
$69.00
Semaglutide is a 31-amino-acid GLP-1 receptor agonist, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
For use by licensed and trained professionals only, operating within their applicable regulations. Not evaluated by the FDA.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg — $39.00 · 10 mg — $59.00 · 20 mg — $89.00 · 30 mg — $129.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 4113.6 g/mol |
| CAS | 910463-68-2 |
| Sequence length | 31 |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | GLP-SEMA |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved under the brand names Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021), with efficacy established across the STEP clinical-trial program.
Semaglutide mimics the incretin hormone GLP-1, binding the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying and act on hypothalamic appetite centers to reduce food intake. Its long half-life comes from fatty-acid acylation and albumin binding, allowing once-weekly dosing in its approved forms.
The STEP trial program established semaglutide's effect on body weight in adults with obesity or overweight, the basis for its approved weight-management indication.
The original approval pathway was type 2 diabetes, with the SUSTAIN trial program establishing glycemic effects.
More recent trials (e.g. SELECT) have examined cardiovascular outcome effects in patients with overweight/obesity and existing cardiovascular disease.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
Yes, as a prescription medication (Ozempic, Wegovy). The bulk research material supplied here is a separate, unapproved-source item intended strictly for use by licensed and trained professionals in supervised programs — it is not the branded, pharmacy-dispensed product.
Further reading: for the published preclinical and clinical literature on Semaglutide, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.